Tamoxifen: the drug that came in from the cold

Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes-Davies, L, Caldas, C, Wishart, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743359/
https://www.ncbi.nlm.nih.gov/pubmed/19672259
http://dx.doi.org/10.1038/sj.bjc.6605231
_version_ 1782171859177963520
author Hughes-Davies, L
Caldas, C
Wishart, G C
author_facet Hughes-Davies, L
Caldas, C
Wishart, G C
author_sort Hughes-Davies, L
collection PubMed
description Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.
format Text
id pubmed-2743359
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27433592010-09-15 Tamoxifen: the drug that came in from the cold Hughes-Davies, L Caldas, C Wishart, G C Br J Cancer Minireview Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS) advantage. Nature Publishing Group 2009-09-15 2009-08-11 /pmc/articles/PMC2743359/ /pubmed/19672259 http://dx.doi.org/10.1038/sj.bjc.6605231 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Hughes-Davies, L
Caldas, C
Wishart, G C
Tamoxifen: the drug that came in from the cold
title Tamoxifen: the drug that came in from the cold
title_full Tamoxifen: the drug that came in from the cold
title_fullStr Tamoxifen: the drug that came in from the cold
title_full_unstemmed Tamoxifen: the drug that came in from the cold
title_short Tamoxifen: the drug that came in from the cold
title_sort tamoxifen: the drug that came in from the cold
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743359/
https://www.ncbi.nlm.nih.gov/pubmed/19672259
http://dx.doi.org/10.1038/sj.bjc.6605231
work_keys_str_mv AT hughesdaviesl tamoxifenthedrugthatcameinfromthecold
AT caldasc tamoxifenthedrugthatcameinfromthecold
AT wishartgc tamoxifenthedrugthatcameinfromthecold

Ejemplares similares